EMA recommends two orphan drugs for approv...The European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended three medicines, two thereof orphan drugs, at its February 2018 meeting. more ➔
Bioeconomy: Bringing in the publicEverybody wants green production. Bioeconomy progress, however, must become more visible to consumers and let the civil society get involved to ensure socially robust innovation and perception, according … more ➔
New Screening method for Antibiotic Discov... A new method that determines the mode of action underlying antimicrobial compounds could help overcome a major stumbling block in the ongoing effort to discover new antibiotics. Using it, reseachers … more ➔
Cullinan Oncology partners with MAB Discov...Virtual oncology company Cullinan Oncology, LLC has selecteed monoclonal antibody provider MAB Discovery GmbH (Neuried) to develop the first candidate of a target portfolio of 8-10 novel … more ➔
Locking malaria parasites into red blood...UK researchers headed by Michael Blackman have found out that a proteolytic cascade regulates release of merozoites of the human malaria parasite Plasmodium falciparum from host red blood cells. … more ➔
PharmaMar in licence deal with Seattle Gen...Spanish specialist for sea-derived synthetic oncology drugs, PharmaMar SA, has inked a licence agreement with US antibody drug conjugate (ADC) company Seattle Genetics Inc. PharmaMar will provide fully-synthetic … more ➔
Roche to pay US$1.9bn for Flatiron HealthIn a strategic acquisition, Roche has completed its capabilities to use Big data to build new business cases in digital diagnostics solutions and personalised healthcare. The pharma major agreed to pay … more ➔
Santhera licenses CF drug from Polyphor Santhera Pharmaceuticals has licenced the inhaled neutrophil eleastase blocker POL6014 from Polyphor Ltd for CHF6.5m upfront and CHF121m in potential milestones. more ➔
AML: Sorafenib boosts graft-versus-leukemi...Co-administration of an allogenic blood stem cell transplant and sorafenib cured AML patients refractive to chemotherapy and stem cell transplants alone, oncologists report in Nature Medicine. more ➔
Poxel in €506m diabetes deal with Roivan...Poxel S.A. is advancing its proof-of-concept type 2 diabetes programme imeglimin (PXL008) into Phase III studies in the US an the EU by means of a licence deal with Swiss Roivant Sciences GmbH. more ➔
